CHO-A POINT PLASTER- methyl salicylate, l-menthol, dl-camphor patch Cho-A Pharm.Co.,Ltd.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Cho-A Point Plaster

Active ingredients

Methyl Salicylate (5.541mg) L-Menthol (2.769mg) Dl-Camphor (1.108mg)

Purpose Topical Analgesic

Directions

Adults and children 12 years of age and over:

- Apply to affected area once a day

Children undress 12 years of age: consult a doctor

Inactive ingredients

Mentha Oil, Tocopherol Acetate, Vanillyl nonylamide, Diphenhydramine, Hydrogenated C6-20 Polyolefin, Stylene · Isoprene · Stylene Block Copolymer, liquid paraffin, polyisobutylene, Butylated Hydroxy Toluene, non woven fabrics, polyethyleneterephthalate Separator

Keep out of reach of children

If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

Warnings

For external use only

Do not use on wounds or damaged skin

- if you are allergic to any ingredients of this product
- with a heating pad
- with, or at the same time as, other external analgesic products

When using this product

- do not use otherwise than directed
- avoid contact with eyes, mucous membranes or rashes
- do not bandage tightly

Ask a doctor before use if you are prone to allergic reaction from aspirin or salicylates

Stop use and ask a doctor if

- rash, itching, or excessive skin irritation develops
- conditions worsen
- symptoms persist for more than 5-6 days
- symptoms clear up and occur again within a few days

If pregnant or breast-feeding, ask a health professional before use.

Uses

For the temporarily relief of minor aches and pains of muscles and joints associated with:

- Arthritis
- Simple backache
- Strains
- bruises
- Sprains

Cho-A Point Plaster



CHO-A POINT PLASTER

| Product Informa | tion | | | | | |
|--|--|--|-----------------------|------------------------|-------------------------|--|
| Product Type | | HUMAN OTC DRUG | Item Code (S | item Code (Source) NDo | | |
| Route of Administra | ation | TOPICAL | | | | |
| Active Ingredien | t/Active N | Aoiety | | | | |
| - | I | ngredient Name | | Basis of Streng | th Strength | |
| CAMPHOR (SYNTHETIC) (UNII: 5TJD82A1ET) (CAMPHOR (SYNTHETIC) - UNII:5TJD82A1ET)CAMPHOR (SYNTHETIC) - (SYNTHETIC) | | | | | 1.108 mg in 67.15 mg | |
| LEVOMENTHOL (UNII: BZ1R15MTK7) (LEVOMENTHOL - UNII:BZ1R15MTK7) | | | | | 2.769 mg in 67.15 mg | |
| METHYL SALICYLA | ATE 5.541 mg in 67.15 mg | | | | | |
| Two etting Tarana It | | | | | | |
| Inactive Ingredie | ents | Ingredient Name | | | Strength | |
| NONIVAMIDE (UNII: S | Strength | | | | | |
| | | | | | | |
| | ROL ACETA | FE (UNII: 9E8X80D2L0) | | | | |
| | | TE (UNII: 9E8X80D2L0)) (UNII: 5XB3A63Y52) | | | | |
| POLYISOBUTYLENI | E (1000 MW) | (UNII: 5XB3A63Y52) | | | | |
| POLYISOBUTYLENI MINERAL OIL (UNII: | E (1000 MW) T5L8T28FGF | (UNII: 5XB3A63Y52) | | | | |
| POLYISOBUTYLENI MINERAL OIL (UNII: | E (1000 MW) T5l8T28FGF XYTOLUEN |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) | | | | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO | E (1000 MW) T5l8T28FGF XYTOLUEN |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) | | | | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE | E (1000 MW) T5l8T28FGF XYTOLUEN |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) | | | | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE Packaging | E (1000 MW) T5l8T28FGF XYTOLUEN |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) | Marl | ceting Start Date | Marketing End Dat | |
| POLYISOBUTYLENI MINERAL O IL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE Packaging # Item Code | E (1000 MW) T5L8 T28 FGF XYTO LUEN (UNII: 8 GTS 8 |) (UNII: 5XB3A63Y52) 2) NE (UNII: 1P9D0Z171K) 32S83M) | Marl 12/28, | 0 | Marketing End Dat | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE | E (1000 MW) T5L8 T28 FGF XYTOLUEN (UNII: 8 GTS8 2 in 1 BOX |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) 32S83M) Package Description | | 0 | Marketing End Dat | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE Packaging // Item Code 1 NDC:58354-104-03 1 NDC:58354-104-02 | E (1000 MW) T5L8 T28 FGF XYTOLUEN (UNII: 8 GTS (UNII: 8 GTS 2 in 1 BOX 60 in 1 POU |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) 32S83M) Package Description | 12/28 | 0 | Marketing End Dat | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE Packaging I tem Code NDC:58354-104-03 NDC:58354-104-02 | E (1000 MW) T5L8 T28 FGF XYTOLUEN (UNII: 8 GTS (UNII: 8 GTS 2 in 1 BOX 60 in 1 POU |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) 32S83M) Package Description CH | 12/28 | 0 | Marketing End Dat | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE Kaging Item Code NDC:58354-104-03 NDC:58354-104-02 NDC:58354-104-01 | E (1000 MW) T5L8 T28 FGF XYTOLUEN (UNII: 8 GTS8 2 in 1 BOX 60 in 1 POU 67.15 mg in |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) B2S83M) Package Description CH 1 PATCH; Type 0: Not a Combinat | 12/28 | 0 | Marketing End Dat | |
| POLYISOBUTYLENI MINERAL OIL (UNII: BUTYLATED HYDRO DIPHENHYDRAMINE Packaging // Item Code 1 NDC:58354-104-03 1 NDC:58354-104-02 | E (1000 MW) T5L8 T28 FGF XYTOLUEN (UNII: 8 GTS8 2 in 1 BOX 60 in 1 POU 67.15 mg in |) (UNII: 5XB3A63Y52) P) NE (UNII: 1P9D0Z171K) B2S83M) Package Description CH 1 PATCH; Type 0: Not a Combinat | tion Product | 0 | Marketing End Date | |

Labeler - Cho-A Pharm.Co.,Ltd. (688056831)

Registrant - Cho-A Pharm.Co.,Ltd. (688056831)

| Establishment | | | | | | | |
|----------------------|---------|-----------|------------------------|--|--|--|--|
| Name | Address | ID/FEI | Business Operations | | | | |
| Cho-A Pharm.Co.,Ltd. | | 688056831 | manufacture(58354-104) | | | | |

Revised: 12/2017

Cho-A Pharm.Co.,Ltd.